免疫抑制
医学
他克莫司
肝移植
肝衰竭
外科
肝病
胃肠病学
肝功能
原位肝移植
病态的
活体肝移植
霉酚酸酯
急性肝衰竭
移植
内科学
作者
Jianjun Zhu,Qiang Xia,Jianjun Zhang,Qigen Li,Xiaosong Chen,Ning Xu
出处
期刊:PubMed
日期:2014-05-01
卷期号:61 (131): 792-4
被引量:1
摘要
Acute liver failure (ALF) is a life-threatening end-stage liver disease, causing high mortality all over the world. Here, we presented a 54-year-old male patient, suffering from drug-induced ALF on the basis of hepatitis B virus (HBV) infection. At that time, the only available donor we could find was his 44-year-old sister. We performed living donor auxiliary partial orthotopic liver transplantation (APOLT) on the second day of admission. The right lobe of the donor liver was implanted into the recipient orthotopically. The actual graft-to-recipient weightratio (GRWR) was 0.85% and the postoperative immunosuppression was a combination of tacrolimus, mycophenolate mofetil (MMF) and steroids. The patient recovered consciousness on the third post-operative day and was discharged with normal liver function after 43 days of transplantation. After a 48-month follow-up, the recipient has been restored to normal life and the immunosuppression has been tapered off (tacrolimus, 1 mg/d). Besides, the size of the native liver has extended to 29% of standard liver volume (SLV) and the native liver cells have returned to normal pathological condition. In conclusion, APOLT is a life-saving treatment for ALF with excellent post-operative outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI